LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Spine/Titan Spine: FDA Clearance for Endoskeleton TL
Spine

Titan Spine: FDA Clearance for Endoskeleton TL

July 18, 2014 2 min read Premium comments

Advertisement

Titan Spine: FDA Clearance for Endoskeleton TL
Endoskeleton TL System / Courtesy: Titan Spine, LLC
Secondary

It’s a slam dunk for Titan Spine, LLC, which has just received clearance from the FDA to commercially release its Endoskeleton TL system, a spinal fusion system that utilizes a lateral approach. As noted by the company, the Endoskeleton TL represents the first lateral fusion device to feature surface technology that is designed to participate in the fusion process by creating an osteogenic response to the implant’s topography.

According to the company, the Endoskeleton TL device utilizes Titan’s proprietary roughened titanium surface technology which has been shown to upregulate the production of osteogenic and angiogenic factors that are critical for bone growth and fusion. In addition, the design of the TL device incorporates large windows and large internal volumes to allow for significant bone graft packing, clear CT and MRI imaging, desired bone graft loading, and the ability to pack additional bone graft material within the device following implantation.

Kade Huntsman, M.D., an orthopedic spine surgeon with the Salt Lake Orthopaedic Clinic in Salt Lake City, Utah, performed the first surgeries utilizing the Endoskeleton TL on July 9, 2014. In the July 14, 2014 news release he said, “I was extremely pleased with the performance of the system. For the first time, I was able to insert additional bone graft material in to a lateral device post-implantation, and the radiopaque nature of the TL made it extremely easy to place the device in the desired location. I am excited to offer the TL, and the benefits of its surface technology and design features, to my patients requiring lateral interbody fusion.”

Andrew Shepherd, vice president of marketing for Titan, told OTW, “We are proud to be the first company to launch a lateral interbody device that features surface technology. The fact that we work closely with biomaterial academic thought leaders in the design of our surface technology highlights that our interbody devices, including the TL, are rooted in science. And while design features are extremely important, we know that our patients primarily benefit from the response that their cells have to the surface topography and associated surface energy of our implants. Encouraging and hastening the body’s own natural healing process will always be our focus as we continue the development of next-generation surface technologies. I am proud and confident to proclaim that Titan Spine is the leader in surface technology for spinal implant applications.”

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy